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See also the general COVID-19 Novel Coronavirus FAQ.
Recently Added
Frequently Asked Questions: Are pregnant healthcare personnel at increased risk for adverse outcomes if they care
for patients with COVID-19?
Q: What are the clinical features of COVID-19?
A: The clinical spectrum of COVID-19 ranges from mild disease with non-specific signs and symptoms of acute respiratory
illness, to severe pneumonia with respiratory failure and septic shock. There have also been reports of asymptomatic
infection with COVID-19. See also Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus
Disease 2019 (COVID-19).
Q: Who is at risk for COVID-19?
A: Currently, those at greatest risk of infection are persons who have had prolonged, unprotected close contact with a
patient with symptomatic, confirmed COVID-19 and those who live in or have recently been to areas with sustained
transmission.
Q: Who is at risk for severe disease from COVID-19?
The available data are currently insufficient to identify risk factors for severe clinical outcomes. From the limited data that
are available for COVID-19 infected patients, and for data from related coronaviruses such as SARS-CoV and MERS-CoV, it
is possible that older adults, and persons who have underlying chronic medical conditions, such as
immunocompromising conditions, may be at risk for more severe outcomes. See also See also Interim Clinical Guidance
for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).
Q: When is someone infectious?
A: The onset and duration of viral shedding and period of infectiousness for COVID-19 are not yet known. It is possible
that SARS-CoV-2 RNA may be detectable in the upper or lower respiratory tract for weeks after illness onset, similar to
infection with MERS-CoV and SARS-CoV. However, detection of viral RNA does not necessarily mean that infectious virus is
present. Asymptomatic infection with SARS-CoV-2 has been reported, but it is not yet known what role asymptomatic
infection plays in transmission. Similarly, the role of pre-symptomatic transmission (infection detection during the
incubation period prior to illness onset) is unknown. Existing literature regarding SARS-CoV-2 and other coronaviruses
(e.g. MERS-CoV, SARS-CoV) suggest that the incubation period may range from 2–14 days.
Q: Which body fluids can spread infection?
A: Very limited data are available about detection of SARS-CoV-2 and infectious virus in clinical specimens. SARS-CoV-2
RNA has been detected from upper and lower respiratory tract specimens, and SARS-CoV-2 has been isolated from upper
respiratory tract specimens and bronchoalveolar lavage fluid. SARS-CoV-2 RNA has been detected in blood and stool
specimens, but whether infectious virus is present in extrapulmonary specimens is currently unknown. The duration of
SARS-CoV-2 RNA detection in upper and lower respiratory tract specimens and in extrapulmonary specimens is not yet
known but may be several weeks or longer, which has been observed in cases of MERS-CoV or SARS-CoV infection. While
viable, infectious SARS-CoV has been isolated from respiratory, blood, urine, and stool specimens, in contrast – viable,
infectious MERS-CoV has only been isolated from respiratory tract specimens. It is not yet known whether other non-
respiratory body fluids from an infected person including vomit, urine, breast milk, or semen can contain viable,
infectious SARS-CoV-2.
Q: Can people who recover from COVID-19 be infected again?
A: The immune response to COVID-19 is not yet understood. Patients with MERS-CoV infection are unlikely to be re-
infected shortly after they recover, but it is not yet known whether similar immune protection will be observed for
patients with COVID-19.
Q: How should healthcare personnel protect themselves when evaluating a patient who may have COVID-
19?
A: Although the transmission dynamics have yet to be determined, CDC currently recommends a cautious approach to
persons under investigation (PUI) for COVID-19. Healthcare personnel evaluating PUI or providing care for patients with
confirmed COVID-19 should use, Standard  Transmission-based Precautions. See the Interim Infection Prevention and
Control Recommendations for Patients with Known or Patients Under Investigation for Coronavirus Disease 2019 (COVID-
19) in Healthcare Settings.
Q: Are pregnant healthcare personnel at increased risk for adverse outcomes if they care for patients with
COVID-19?
A: Pregnant healthcare personnel (HCP) should follow risk assessment and infection control guidelines for HCP exposed
to patients with suspected or confirmed COVID-19. Adherence to recommended infection prevention and control
practices is an important part of protecting all HCP in healthcare settings. Information on COVID-19 in pregnancy is very
limited; facilities may want to consider limiting exposure of pregnant HCP to patients with confirmed or suspected COVID-
19, especially during higher risk procedures (e.g., aerosol-generating procedures) if feasible based on staffing availability.
Q: Should any diagnostic or therapeutic interventions be withheld due to concerns about transmission of
COVID-19?
A: Patients should receive any interventions they would normally receive as standard of care. Patients with suspected or
confirmed COVID-19 should be asked to wear a surgical mask as soon as they are identified and be evaluated in a private
room with the door closed. Healthcare personnel entering the room should use Standard and Transmission-based
Precautions.
Q: How do you test a patient for SARS-CoV-2, the virus that causes COVID-19?
A: See recommendations for reporting, testing, and specimen collection at Interim Guidance for Healthcare Professionals
Q: Will existing respiratory virus panels, such as those manufactured by Biofire or Genmark, detect SARS-
CoV-2, the virus that causes COVID-19?
A: No. These multi-pathogen molecular assays can detect a number of human respiratory viruses, including other
coronaviruses that can cause acute respiratory illness, but they do not detect COVID-19.
Q: How is COVID-19 treated?
Not all patients with COVID-19 will require medical supportive care. Clinical management for hospitalized patients with
COVID-19 is focused on supportive care of complications, including advanced organ support for respiratory failure, septic
shock, and multi-organ failure. Empiric testing and treatment for other viral or bacterial etiologies may be warranted.
Corticosteroids are not routinely recommended for viral pneumonia or ARDS and should be avoided unless they are
indicated for another reason (e.g., COPD exacerbation, refractory septic shock following Surviving Sepsis Campaign
Guidelines).
There are currently no antiviral drugs licensed by the U.S. Food and Drug Administration (FDA) to treat COVID-19. Some
in-vitro or in-vivo studies suggest potential therapeutic activity of some agents against related coronaviruses, but there
are no available data from observational studies or randomized controlled trials in humans to support recommending
any investigational therapeutics for patients with confirmed or suspected COVID-19 at this time. Remdesivir, an
investigational antiviral drug, was reported to have in-vitro activity against COVID-19. A small number of patients with
COVID-19 have received intravenous remdesivir for compassionate use outside of a clinical trial setting. A randomized
placebo-controlled clinical trial of remdesivir  for treatment of hospitalized patients with COVID-19 respiratory disease
has been implemented in China. A randomized open label trial  of combination lopinavir-ritonavir treatment has been
also been conducted in patients with COVID-19 in China, but no results are available to date. trials of other potential
therapeutics for COVID-19 are being planned. For information on specific clinical trials underway for treatment of
patients with COVID-19 infection, see clinicaltrials.gov .
See Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19)
Q: Should post-exposure prophylaxis be used for people who may have been exposed to COVID-19?
A: There is currently no FDA-approved post-exposure prophylaxis for people who may have been exposed to COVID-19.
For more information on movement restrictions, monitoring for symptoms, and evaluation after possible exposure to
COVID-19 See Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential
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Coronavirus Disease 2019 (COVID-19) Exposure in Travel-associated or Community Settings and Interim U.S Guidance for
Risk Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting
to Patients with Coronavirus Disease 2019 (COVID-19).
Q: Whom should healthcare providers notify if they suspect a patient has COVID-19?
A: Healthcare providers should consult with local or state health departments to determine whether patients meet
criteria for a Persons Under Investigation (PUI). Providers should immediately notify infection control personnel at their
facility if they suspect COVID-19 in a patient.
Q: Do patients with confirmed or suspected COVID-19 need to be admitted to the hospital?
A: Not all patients with COVID-19 require hospital admission. Patients whose clinical presentation warrants in-patient
clinical management for supportive medical care should be admitted to the hospital under appropriate isolation
precautions. Some patients with an initial mild clinical presentation may worsen in the second week of illness. The
decision to monitor these patients in the inpatient or outpatient setting should be made on a case-by-case basis. This
decision will depend not only on the clinical presentation, but also on the patient’s ability to engage in monitoring, the
ability for safe isolation at home, and the risk of transmission in the patient’s home environment. For more information,
see Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation
for Coronavirus Disease 2019 (COVID-19) in a Healthcare Setting and Interim Guidance for Implementing Home Care of
People Not Requiring Hospitalization for Coronavirus Disease 2019 (COVID-19).
Q: When can patients with confirmed COVID-19 be discharged from the hospital?
A: Patients can be discharged from the healthcare facility whenever clinically indicated. Isolation should be maintained at
home if the patient returns home before the time period recommended for discontinuation of hospital Transmission-
Based Precautions described below.
Decisions to discontinue Transmission-Based Precautions or in-home isolation can be made on a case-by-case basis in
consultation with clinicians, infection prevention and control specialists, and public health based upon multiple factors,
including disease severity, illness signs and symptoms, and results of laboratory testing for COVID-19 in respiratory
specimens.
Criteria to discontinue Transmission-Based Precautions can be found in: Interim Considerations for Disposition of
Hospitalized Patients with COVID-19
Q: Are pregnant healthcare personnel at increased risk for adverse outcomes if they care for patients with
COVID-19?
A: Pregnant healthcare personnel (HCP) should follow risk assessment and infection control guidelines for HCP exposed
to patients with suspected or confirmed COVID-19. Adherence to recommended infection prevention and control
practices is an important part of protecting all HCP in healthcare settings. Information on COVID-19 in pregnancy is very
limited; facilities may want to consider limiting exposure of pregnant HCP to patients with confirmed or suspected COVID-
19, especially during higher risk procedures (e.g., aerosol-generating procedures) if feasible based on staffing availability.
Q: What do I need to know if a patient with confirmed or suspected COVID-19 asks about having a pet or
other animal in the home?
A: See COVID-19 and Animals.
Waste Management QAs
Q: What do waste management companies need to know about wastewater and sewage coming from a
healthcare facility or community setting with either a known COVID-19 patient or person under investigation
(PUI)?
A: Waste generated in the care of PUIs or patients with confirmed COVID-19 does not present additional considerations
for wastewater disinfection in the United States. Coronaviruses are susceptible to the same disinfection conditions in
community and healthcare settings as other viruses, so current disinfection conditions in wastewater treatment facilities
are expected to be sufficient. This includes conditions for practices such as oxidation with hypochlorite (i.e., chlorine
bleach) and peracetic acid, as well as inactivation using UV irradiation.
Q: Do wastewater and sewage workers need any additional protection when handling untreated waste from
healthcare or community setting with either a known COVID-19 patient or PUI?
A: Wastewater workers should use standard practices including basic hygiene precautions and wear the recommended
PPE as prescribed for their current work tasks when handling untreated waste. There is no evidence to suggest that
employees of wastewater plants need any additional protections in relation to COVID-19.
Q: Should medical waste or general waste from healthcare facilities treating PUIs and patients with
confirmed COVID-19 be handled any differently or need any additional disinfection?
A: Medical waste (trash) coming from healthcare facilities treating COVID-2019 patients is no different than waste coming
from facilities without COVID-19 patients. CDC’s guidance states that management of laundry, food service utensils, and
medical waste should be performed in accordance with routine procedures. There is no evidence to suggest that facility
waste needs any additional disinfection.
More guidance about environmental infection control is available in section 7 of CDC’s Interim Infection Prevention and
Control Recommendations for Patients with Confirmed COVID-19 or Persons Under Investigation for COVID-19 in
Healthcare Settings.
Additional Resources:
CDC Infection Control Environmental Infection Control Guidance
OSHA 2019 Novel Coronavirus website
Detailed information on environmental infection control in healthcare settings can be found in CDC’s Guidelines for
Environmental Infection Control in Health-Care Facilities
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